Amy S. Paller, MD

Articles by Amy S. Paller, MD

Significance of ADorable-1 Data on Lebrikizumab in Children with Atopic Dermatitis, With Amy Paller, MD

March 17th 2026

Following the release of new results from the phase 3 ADorable-1 trial on lebrikizumab in pediatric patients, Amy Paller, MD, speaks in a new Q&A interview.

Reacting to FDA Approval of Ruxolitinib for Pediatric Atopic Dermatitis, with Amy Paller, MD

ByAmy S. Paller, MD

September 18th 2025

This interview with Amy Paller, MD, highlights the significance of the approval of ruxolitinib for the treatment of pediatric atopic dermatitis.

Atopic Dermatitis Burden Among Families of Children Under 6 Years, with Amy S. Paller, MD

ByAmy S. Paller, MD

June 11th 2025

In this RAD 2025 interview, Paller highlights her team’s findings on disease and family burden of topic dermatitis in children.

Amy S. Paller, MD

Articles by Amy S. Paller, MD

Significance of ADorable-1 Data on Lebrikizumab in Children with Atopic Dermatitis, With Amy Paller, MD

Reacting to FDA Approval of Ruxolitinib for Pediatric Atopic Dermatitis, with Amy Paller, MD

Atopic Dermatitis Burden Among Families of Children Under 6 Years, with Amy S. Paller, MD

Latest Updated Articles

Trending on HCPLive

SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study

Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B

Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial

Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs

What Are the Side Effects of Hair and Skin Supplements in Dermatology? With Rajani Katta, MD